Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data

By: via Benzinga
Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.